Dietary Treatment Study of Pediatric NAFLD
DTS
Randomized, Controlled Dietary Treatment Study of Pediatric NAFLD
1 other identifier
interventional
40
1 country
2
Brief Summary
This is an investigator initiated study being conducted in equal numbers at two sites, University of California, San Diego (UC San Diego) and Emory University (EU). The purpose of this study is to understand the potential of a low sugar diet for the treatment of nonalcoholic fatty liver disease (NAFLD) in children. Forty boys with NAFLD will be randomly assigned to either an intervention group or a habitual diet control group. The intervention will be a low sugar diet for a period of 8 weeks. The effect of this dietary change will be assessed using advanced magnetic resonance imaging (MRI) testing to measure liver fat.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for not_applicable
Started Jul 2015
Typical duration for not_applicable
2 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
July 1, 2015
CompletedFirst Submitted
Initial submission to the registry
July 29, 2015
CompletedFirst Posted
Study publicly available on registry
July 31, 2015
CompletedPrimary Completion
Last participant's last visit for primary outcome
August 31, 2017
CompletedStudy Completion
Last participant's last visit for all outcomes
August 31, 2017
CompletedResults Posted
Study results publicly available
January 28, 2020
CompletedJanuary 28, 2020
January 1, 2020
2.2 years
July 29, 2015
June 26, 2019
January 16, 2020
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Change in Percentage of Liver Fat Measured by Magnetic Resonance Imaging (MRI) in the Intervention Group Compared to Change in the Control Group
The principal objective of this randomized and controlled pilot study is to evaluate whether 8 weeks of a low added sugar diet (\<3%) in boys with NAFLD will change liver fat % measured by MRI.
Measurements done at baseline and week 8.
Secondary Outcomes (6)
Change in Alanine Aminotransferase (ALT) From Baseline to Week 8
Measurements done at baseline and week 8
Change in Aspartate Aminotransferase (AST) From Baseline to Week 8
Measurements doen at baseline and week 8
Change in Gamma-Glutamyl Transpeptidase (GGT) From Baseline to Week 8
Measurements done at baseline and week 8
Change in Insulin From Baseline to Week 8
Measurements done at baseline and week 8
Change in Homeostasis Model Assessment- Insulin Resistance (HOMA-IR) From Baseline to Week 8
Measurements done at baseline and week 8
- +1 more secondary outcomes
Study Arms (2)
Dietary modification
ACTIVE COMPARATORLow free sugar diet
Observational Arm
NO INTERVENTIONStandard of care
Interventions
The intervention is a modification of the family's habitual diet with a low sugar version of their diet.
Eligibility Criteria
You may qualify if:
- Boys age 11-16 years inclusive.
- Clinical history consistent with NAFLD.
- Biopsy-proven NAFLD
- MRI measured Liver Proton Density Fat Fraction ≥10%
- alanine aminotransferase (ALT) ≥ 45 u/L
- No evidence of any other liver disease by clinical history or histological evaluation.
- Written informed consent from parent or legal guardian.
- Written informed assent from the child or adolescent.
You may not qualify if:
- History of significant alcohol intake (Alcohol Use Disorders Identification Test \[AUDIT\]) or inability to quantify alcohol consumption
- Chronic use (more than 2 consecutive weeks) of medications known to cause hepatic steatosis or steatohepatitis in the past year.
- The use of other known hepatotoxins within 120 days of baseline
- History of total parenteral nutrition (TPN) use in the year prior to screening
- History of bariatric surgery or planning to undergo bariatric surgery during the study duration
- Significant depression
- Non-compensated liver disease with any one of the following hematologic, biochemical, and serological criteria on entry into protocol:
- Hemoglobin \< 10 g/dL
- White blood cell \< 3,500 cells/mm
- Neutrophil count \< 1,500 cells/mm3 of blood
- Platelets \< 130,000 cells/mm3 of blood
- Direct bilirubin \> 1.0 mg/dL
- Total bilirubin \> 3 mg/dL
- Albumin \< 3.2 g/dL
- International normalized ratio (INR) \> 1.4
- +7 more criteria
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- University of California, San Diegolead
- Emory Universitycollaborator
- Nutrition Science Initiativecollaborator
Study Sites (2)
University of California, San Diego
San Diego, California, 92093, United States
Emory University
Atlanta, Georgia, 30322, United States
Related Publications (9)
Schwimmer JB, Deutsch R, Rauch JB, Behling C, Newbury R, Lavine JE. Obesity, insulin resistance, and other clinicopathological correlates of pediatric nonalcoholic fatty liver disease. J Pediatr. 2003 Oct;143(4):500-5. doi: 10.1067/S0022-3476(03)00325-1.
PMID: 14571229BACKGROUNDSchwimmer JB, Deutsch R, Kahen T, Lavine JE, Stanley C, Behling C. Prevalence of fatty liver in children and adolescents. Pediatrics. 2006 Oct;118(4):1388-93. doi: 10.1542/peds.2006-1212.
PMID: 17015527BACKGROUNDSchwimmer JB, Pardee PE, Lavine JE, Blumkin AK, Cook S. Cardiovascular risk factors and the metabolic syndrome in pediatric nonalcoholic fatty liver disease. Circulation. 2008 Jul 15;118(3):277-83. doi: 10.1161/CIRCULATIONAHA.107.739920. Epub 2008 Jun 30.
PMID: 18591439BACKGROUNDJin R, Le NA, Liu S, Farkas Epperson M, Ziegler TR, Welsh JA, Jones DP, McClain CJ, Vos MB. Children with NAFLD are more sensitive to the adverse metabolic effects of fructose beverages than children without NAFLD. J Clin Endocrinol Metab. 2012 Jul;97(7):E1088-98. doi: 10.1210/jc.2012-1370. Epub 2012 Apr 27.
PMID: 22544914BACKGROUNDJin R, Welsh JA, Le NA, Holzberg J, Sharma P, Martin DR, Vos MB. Dietary fructose reduction improves markers of cardiovascular disease risk in Hispanic-American adolescents with NAFLD. Nutrients. 2014 Aug 8;6(8):3187-201. doi: 10.3390/nu6083187.
PMID: 25111123BACKGROUNDSchwimmer JB, Middleton MS, Behling C, Newton KP, Awai HI, Paiz MN, Lam J, Hooker JC, Hamilton G, Fontanesi J, Sirlin CB. Magnetic resonance imaging and liver histology as biomarkers of hepatic steatosis in children with nonalcoholic fatty liver disease. Hepatology. 2015 Jun;61(6):1887-95. doi: 10.1002/hep.27666. Epub 2015 Feb 5.
PMID: 25529941BACKGROUNDJin R, Vos MB. Fructose and liver function--is this behind nonalcoholic liver disease? Curr Opin Clin Nutr Metab Care. 2015 Sep;18(5):490-5. doi: 10.1097/MCO.0000000000000203.
PMID: 26203597BACKGROUNDCohen CC, Li KW, Alazraki AL, Beysen C, Carrier CA, Cleeton RL, Dandan M, Figueroa J, Knight-Scott J, Knott CJ, Newton KP, Nyangau EM, Sirlin CB, Ugalde-Nicalo PA, Welsh JA, Hellerstein MK, Schwimmer JB, Vos MB. Dietary sugar restriction reduces hepatic de novo lipogenesis in adolescent boys with fatty liver disease. J Clin Invest. 2021 Dec 15;131(24):e150996. doi: 10.1172/JCI150996.
PMID: 34907907DERIVEDSchwimmer JB, Ugalde-Nicalo P, Welsh JA, Angeles JE, Cordero M, Harlow KE, Alazraki A, Durelle J, Knight-Scott J, Newton KP, Cleeton R, Knott C, Konomi J, Middleton MS, Travers C, Sirlin CB, Hernandez A, Sekkarie A, McCracken C, Vos MB. Effect of a Low Free Sugar Diet vs Usual Diet on Nonalcoholic Fatty Liver Disease in Adolescent Boys: A Randomized Clinical Trial. JAMA. 2019 Jan 22;321(3):256-265. doi: 10.1001/jama.2018.20579.
PMID: 30667502DERIVED
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Results Point of Contact
- Title
- Dr. Jeffrey Schwimmer
- Organization
- University of California, San Diego
Study Officials
- PRINCIPAL INVESTIGATOR
Jeffrey B Schwimmer, MD
University of California, San Diego
- PRINCIPAL INVESTIGATOR
Miriam Vos, MD
Emory University
Publication Agreements
- PI is Sponsor Employee
- No
- Restrictive Agreement
- No
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- NONE
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Professor of Pediatrics
Study Record Dates
First Submitted
July 29, 2015
First Posted
July 31, 2015
Study Start
July 1, 2015
Primary Completion
August 31, 2017
Study Completion
August 31, 2017
Last Updated
January 28, 2020
Results First Posted
January 28, 2020
Record last verified: 2020-01
Data Sharing
- IPD Sharing
- Will share
De-identified participant data will be made available in response to bona fide and good faith, ad hoc requests. Suitability of each request, if consistent with Institutional Review Board (IRB) approval, will be determined only in the case of a favorable vote of a majority of a committee consisting of each consortium investigator and the Grantor. Data will be made available with a signed access agreement.